SCHEMBL1119940

SCHEMBL1119940

Cc1ccc(-c2c[nH][c]n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.42
METAP1 P53582 1/20 0.42
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 2/20 0.38
NOTUM Q6P988 1/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
ENPP3 O14638 1/20 0.37
ENPP1 P22413 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
ALPL P05186 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MITF O75030 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202001 0.79 NOTUM (0.42) METAP2KMT2AMEN1POLBNOTUM
SCHEMBL27606211 0.79 METAP2 (0.42) METAP2KMT2AMEN1LMNARAB9A
SCHEMBL27584582 0.79 METAP2 (0.42) METAP2KMT2AMEN1LMNAPOLB
SCHEMBL4047707 0.79 AKT1 (0.42) METAP2KMT2AMEN1LMNAPOLB
SCHEMBL4046110 0.79 RAB9A (0.37) KMT2AMEN1POLBRAB9ANPC1
SCHEMBL1317405 0.79 NPC1 (0.46) KMT2AMEN1LMNAPOLBRAB9A
SCHEMBL27554388 0.79 METAP2 (0.47) METAP2KMT2AMEN1LMNANOTUM
SCHEMBL27584597 0.79 KIF11 (0.42) KMT2AMEN1LMNAPOLBNOTUM
SCHEMBL63014 0.78 RAB9A (0.41) METAP2KMT2AMEN1POLBNOTUM
SCHEMBL7179987 0.77 LMNA (0.42) KMT2ALMNANOTUMRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-2280941-A1 (HETERO-)ARYL CYCLOHEXANE DERIVATIVES Grünenthal GmbH (DE) 2011-02-09 EP disclosed
WO-2009118163-A1 (HETERO-)ARYL CYCLOHEXANE DERIVATIVES Grünenthal GmbH (DE) 2009-10-01 WO disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 METAP2 4360/4885METAP1 4692/4885KMT2A 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.